RxDoctor Payments Data

Teresa Affrunti

Family · Highlands Ranch, CONPI 1316427495

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (41.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Painteq LLC at 27.3% of the total. Reporting peaked in 2022 at $6,949 and has fallen 96.9% since, to $214 in 2025. Among family clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,166in general payments, 2019–2025

Across 366 payments — averaging $55.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Painteq LLC$6K
  • Boston Scientific$3K
  • Saluda Medical Americas, Inc.$2K
  • Medtronic$2K
  • AbbVie$1K
  • Vertos Medical, Inc.$1K
  • plus $5K from 24 others

What the payments were for

  • Consulting fees$5,45427%
  • Travel & lodging$6,31831%
  • Food & beverage$8,34041%
  • Education$540%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,166 in reported general payments places this provider in the 95th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$123,358
Medicare patients
210
Services billed
1,320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl74$63,321
Xtampza ErOxycodone Myristate117$42,365
Buprenorphine112$21,194
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen522$15,646
MovantikNaloxegol Oxalate33$15,639
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen446$15,038
Oxycodone Hcl569$11,078
SymproicNaldemedine Tosylate19$8,853
Morphine Sulfate ErMorphine Sulfate338$8,831
Nucynta ErTapentadol Hcl15$8,731
Gabapentin276$7,364
Hysingla ErHydrocodone Bitartrate15$5,422
Lidocaine25$2,814
Pregabalin103$2,666
Fentanyl30$2,618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er$927$114,417206 claims
Redhill Biopharma Inc.Movantik$19$15,63933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,182 family providers in Colorado.

Other family in Highlands Ranch

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →